Advanced & Next-Gen Proteomics - Head of Diagnostics, Top 15 Pharma

A biopharma diagnostics executive discusses how proteomics technologies are leveraged in their oncology portfolio for understanding disease biology and mechanisms of resistance. Their definition of next generation proteomics involves new technologies for ultra-sensitive, highly plexed, and single cell level applications, but these are still early for clinical applications. The stakeholder lists Luminex, MSD, and Quanterix as top companies in the multiplex immunoassay space, mass spec for metabolite profiling, and is also very familiar with Olink. The top three applications of next generation proteomics in the stakeholder's research are therapeutic response monitoring, biomarker discovery, and single cell proteomics. Therapeutic response monitoring involves monitoring pharmacodynamic and pharmacokinetic responses, cytokine release storms, and immune reactivity in clinical oncology. Biomarker discovery and single cell proteomics are applied for earlier stage R&D.

‍